197 related articles for article (PubMed ID: 32857656)
41. Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension.
Gatwood J; Hohmeier KC; Shuvo S; Mikaiel D; Kovesdy CP
J Manag Care Spec Pharm; 2021 Apr; 27(4):497-506. PubMed ID: 33769854
[No Abstract] [Full Text] [Related]
42. The Effect of Reduced Drug Copayments on Adherence to Oral Diabetes Medications Among Childless Adults in Wisconsin Medicaid.
Kim NH; Look KA
J Manag Care Spec Pharm; 2019 Dec; 25(12):1432-1441. PubMed ID: 31778619
[TBL] [Abstract][Full Text] [Related]
43. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
[TBL] [Abstract][Full Text] [Related]
44. The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US.
Hepp Z; Lage MJ; Espaillat R; Gossain VV
J Med Econ; 2018 Sep; 21(9):912-919. PubMed ID: 29865926
[TBL] [Abstract][Full Text] [Related]
45. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
46. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
[TBL] [Abstract][Full Text] [Related]
47. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
48. Clinical and economic outcomes in medication-adherent and -nonadherent patients with type 2 diabetes mellitus in the Republic of Korea.
An SY; Kim HJ; Chun KH; Kim TH; Jeon JY; Kim DJ; Han SJ; Kim YS; Woo JT; Ahn KJ; Park Y; Nam M; Baik SH; Lee KW
Clin Ther; 2014 Feb; 36(2):245-54. PubMed ID: 24480636
[TBL] [Abstract][Full Text] [Related]
49. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy.
Deshpande CG; Kogut S; Willey C
J Manag Care Spec Pharm; 2018 May; 24(5):430-439. PubMed ID: 29694285
[TBL] [Abstract][Full Text] [Related]
50. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
51. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
52. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
[TBL] [Abstract][Full Text] [Related]
53. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
[TBL] [Abstract][Full Text] [Related]
54. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
55. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
56. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
57. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database.
Kirkman MS; Rowan-Martin MT; Levin R; Fonseca VA; Schmittdiel JA; Herman WH; Aubert RE
Diabetes Care; 2015 Apr; 38(4):604-9. PubMed ID: 25573883
[TBL] [Abstract][Full Text] [Related]
58. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
59. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
60. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]